NASDAQ · NVNO
Healthcare · Medical - Devices
$10.49
Down-$0.63 (-5.67%)
Updated Sep 12, 2026, 12:34 PM
SID Score
3.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
NVNO closed at $10.49 after 20 trading sessions, down 4.55% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $11.49 | $11.65 | $9.97 | $10.49 | 55.59K |
| Sep 10, 2026 | $11.38 | $11.675 | $11.10 | $11.12 | 60.93K |
| Sep 9, 2026 | $11.4121 | $11.82 | $10.85 | $11.10 | 94.42K |
| Sep 8, 2026 | $11.31 | $11.62 | $11.16 | $11.49 | 4.18K |
| Sep 4, 2026 | $11.05 | $11.4393 | $11.05 | $11.4393 | 2.11K |
| Sep 3, 2026 | $11.42 | $11.42 | $11.00 | $11.10 | 2.43K |
| Sep 2, 2026 | $11.44 | $11.5499 | $11.21 | $11.30 | 4.78K |
| Sep 1, 2026 | $11.36 | $11.36 | $10.53 | $10.98 | 42.2K |
| Aug 31, 2026 | $10.51 | $11.47 | $10.255 | $11.47 | 24.94K |
| Aug 28, 2026 | $10.80 | $10.80 | $10.665 | $10.75 | 3.19K |
| Aug 27, 2026 | $11.5285 | $11.94 | $11.20 | $11.24 | 6.87K |
| Aug 26, 2026 | $11.299 | $11.95 | $10.805 | $11.4678 | 17.3K |
| Aug 25, 2026 | $10.70 | $11.17 | $10.335 | $10.80 | 3.88K |
| Aug 24, 2026 | $10.59 | $11.41 | $10.30 | $10.35 | 20.28K |
| Aug 21, 2026 | $10.78 | $11.15 | $10.13 | $10.29 | 21.2K |
| Aug 20, 2026 | $10.44 | $11.59 | $10.17 | $10.39 | 26.94K |
| Aug 19, 2026 | $11.25 | $11.25 | $10.48 | $10.48 | 28.53K |
| Aug 18, 2026 | $12.00 | $12.49 | $10.725 | $11.035 | 25.16K |
| Aug 17, 2026 | $11.09 | $12.31 | $10.15 | $11.80 | 7.79K |
| Aug 14, 2026 | $10.80 | $10.99 | $10.71 | $10.99 | 1.49K |
The latest Smart Investors Daily articles mentioning NVNO.
NVNO research
Company profile and research snapshot.
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Visit company websiteConsensus and target data currently published for this company.
Generated Sep 11, 2026, 9:23 PM
enVVeno Medical shares declined 5.67% today despite the company making its H.C. Wainwright Conference presentation available on-demand. The lack of significant positive catalysts combined with broader market conditions appears to be weighing on investor sentiment for the medical device company.
Bottom line: enVVeno Medical's stock decline today appears disconnected from any negative company-specific news, suggesting market-wide pressure or a muted investor response to the H.C. Wainwright Conference presentation. Investors should monitor for substantive developments or announcements stemming from the conference while remaining aware that medical device stocks can be volatile around investor events. Key catalysts to watch include clinical data releases, partnership announcements, or revenue guidance updates.
Yahoo · Sep 11, 2026
Access the video webcast hereIRVINE, CA / ACCESS Newswire / September 11, 2026 / (NASDAQ:NVNO) ("enVVeno Medical" or the "Company"), today announced that its pre-recorded presentation from the H. Wainwright 28th Annual Global Investment Conference is now available for on-demand viewing here.
Benzinga · Aug 21, 2026
-SEC Filing
Benzinga · Aug 4, 2026
Published economic health study shows both short- and long-term cost-effectiveness of replacement venous value therapy versus standard-of-care treatments for deep venous CVI, generating compelling evidence that will be
Benzinga · Jul 31, 2026
enVVeno Medical (NASDAQ:NVNO) reported quarterly losses of $(5.37) per share. This is a 53.51 percent increase over losses of $(11.55) per share from the same period last year.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NVNO.
